Are you looking for the technical information about MT-DADMe-ImmA? Get brief information over here will help you to know more about the same. So, this is an inhibitor of 5′-methylthioadenosine phosphorylase (MTAP; Ki = 1.7 nM) and it is known to increase levels of MTA along with a product of polyamine metabolism.

When we talk about the biological activity of Dadme, it is said that the treatment of cultured cells with MT-DADMe-ImmA and MTA inhibit MTAP, helps in increasing cellular MTA concentrations, at the same time, it decreases polyamines, and induces apoptosis in FaDu and Cal27, two head and neck squamous cell carcinoma cell lines. Also know that the same treatment does not induce apoptosis in normal human fibroblast cell lines and a breast cancer cell line with an MTAP gene deletion. You should know that MT-DADMe-ImmA alone does not induce apoptosis in any cell line, implicating MTA as the active agent. Also, MCE has not independently confirmed the accuracy of these methods.

Apart from this, if you would like to know more on DS-1205, you must know it is also known as DS-1205b, which is a selective and potent AXL kinase inhibitor with IC50 of 1.3 nM. This helps in potently inhibited the hGAS6-induced migration in vitro with EC50 of 2.7 nM and its monotherapy exerted significant antitumor activity in an NIH3T3-AXL allograft model. It must be noted that DS-1205b restored the antitumor activity of erlotinib in erlotinib-resistant and it can also be delayed the onset of resistance when used in combination with osimertinib in the model. These findings provide information that DS-1205b can prolong the therapeutic benefit of EGFR TKIs in nonclinical as well as clinical settings. It is important to check for Dose Escalation along with the safety and tolerability of DS-1205c when combined with osimertinib in the study population and to determine the recommended dose for expansion of DS-1205c when combined with osimertinib in the study population.